Related Experiment Video
Updated: Dec 24, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate
Muhammad O Niaz1, Michael Sun2, Marigdalia K Ramirez-Fort3,4,5
1Internal Medicine, Sharif Medical City Hospital, Lahore, PAK.
Abstract:
Cancer cells can be selectively targeted by identifying and developing antibodies to specific antigens present on the cancer cell surface. Cytotoxic agents can be conjugated to these antibodies that bind to these cell surface antigens in order to significantly increase the therapeutic index of whichever cytotoxic agent is utilized. This approach of conjugating the cytotoxic drugs to antibodies to target specific surface antigens enhances the anti-tumor activity of antibodies and improves the tumor-to-normal tissue selectivity of chemotherapy. Critical parameters in the development of these antibody-drug conjugates include: 1) selection of most appropriate antigen, 2) the ability of an antibody to be internalized after binding to the antigen, 3) cytotoxic drug potency and 4) stability of the antibody-drug conjugate. For prostate cancer, prostate-specific membrane antigen (PSMA, also known as folate hydrolase-1) is the most validated theragnostic target to date. PSMA is overexpressed on the prostate cancer cell surface, which makes it an even better target for selective drug delivery through conjugated antibodies. Here, we review the PSMA-based antibody-drug conjugates for metastatic castration-resistance prostate cancer (mCRPC).
Insights
Antibody-drug conjugates target cancer cells using specific antigens. This review focuses on PSMA-based antibody-drug conjugates for treating metastatic castration-resistant prostate cancer.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) offer targeted cancer therapy by linking cytotoxic agents to antibodies that bind specific cell surface antigens.
- This approach enhances anti-tumor activity and improves selectivity, minimizing damage to normal tissues.
- Key development parameters include antigen selection, antibody internalization, drug potency, and ADC stability.
Purpose of the Study:
- To review the development and application of prostate-specific membrane antigen (PSMA)-based antibody-drug conjugates.
- To highlight PSMA as a validated theragnostic target for prostate cancer.
- To discuss the potential of PSMA-ADCs in treating metastatic castration-resistant prostate cancer (mCRPC).
Main Methods:
- Literature review of PSMA-based antibody-drug conjugates.
- Analysis of critical parameters for ADC development.
- Focus on PSMA as a target antigen for prostate cancer therapy.
Main Results:
- PSMA is overexpressed on prostate cancer cells, making it an ideal target for selective drug delivery.
- PSMA-based ADCs demonstrate significant potential for enhanced anti-tumor activity and tumor selectivity.
- The review covers the current landscape of PSMA-ADCs for mCRPC treatment.
Conclusions:
- PSMA-based antibody-drug conjugates represent a promising therapeutic strategy for metastatic castration-resistant prostate cancer.
- Targeting PSMA offers a highly selective approach for delivering cytotoxic agents directly to prostate cancer cells.
- Further research and development in PSMA-ADCs are warranted to optimize treatment outcomes.
More Related Videos
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018